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Microbiome dysbiosis-associated medical conditions
and natural microbiota as therapeutic agents
Microbiome dysbiosis (Br€ussow, 2016) – the deviation
from a desired, equilibrated, health-associated micro-
biota1 – especially of the major microbial organ, the gas-
trointestinal tract, is being increasingly associated with
diverse medical conditions. The classic disease resulting
from dysbiosis is antibiotic therapy-induced pseudomem-
branous colitis, caused by Clostridium difficile. More
recently, allergies and other, often severe, conditions,
such as inflammatory bowel disease, cancer, psychologi-
cal disorders and various cardiometabolic diseases such
as diabetes mellitus and obesity, have been associated
with microbiota dysbiosis. Cardiometabolic diseases are
of particular importance, as they significantly increase
the risk of developing or exacerbating incident cardiovas-
cular disease – the leading cause of death across the
OECD world (circa 36%) and associated with 17% (on
average) of total healthcare costs (OECD, 2015, 2017).
The list of dysbiosis-disease associations continues to
grow. Causal relationships have, for the most part, not
yet been established, and we are still far from under-
standing pertinent disease aetiology (Br€ussow, 2016).
A central goal of dysbiosis therapy is to provide an
ecological impetus for re-establishment of the microbiota
ecophysiological diversity and functional coherence
needed for ‘healthy’ performance of the relevant surface/
organ/metabolic network. A simple therapy option is to
supplement the dysbiotic microbiota with a sample of
corresponding microbiota from a healthy donor, i.e. fae-
cal microbiota transplantation, a therapy that has
achieved excellent outcomes in the case of C. difficile-
caused colitis (Eiseman et al., 1958; Seal et al., 1989;
Tvede and Rask-Madsen, 1989; van Nood et al., 2013;
Rossen et al., 2015). As a consequence of this success,
a range of new therapeutic interventions for correcting
dysbiosis are being explored, which involve the adminis-
tration of selected live microbes, microbial mixtures and
natural microbial consortia, as well as pre- and probi-
otics, for both therapy and prophylaxis. However, since it
has not yet been established which component(s) of the
faecal sample (entire faecal material, spores – e.g. of
clostridia, the cell-free fraction, the combinations of cer-
tain specific faecal microbes, etc.) in faecal microbiota
transplantation determine(s) its effectiveness, the poten-
tial of novel microbiota therapies must, for the moment,
be viewed with both optimism and caution.
Challenges facing natural microbiota as therapeutic
agents
Important issues related to the use of natural consortia,
such as faecal samples, as therapies for microbiome
dysbiosis are inter alia safety, standardization, repro-
ducibility and quality control. Faeces from apparently
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healthy donors of course contain (low numbers of)
pathogens, which are normal members of the natural
flora, and ordinarily do not cause disease in otherwise
healthy individuals. Sometimes, however, they may con-
tain infectious agents that qualitatively (e.g. hepatitis
virus, HIV, Campylobacter, Helicobacter, etc.) or quanti-
tatively pose a significant risk for patient safety. More-
over, there exists a high level of diversity and variability
in microbiota compositions among individuals, and within
individuals over time, so achieving standardization of
donor samples is a major challenge (Costello et al.,
2009; Rajilic-Stojanovic et al., 2012). Perhaps of even
more concern is the fact that both dysbiosis and poten-
tial therapies currently constitute black boxes, with little
or no understanding of underlying processes, regulatory
controls and switches, and causal relationships. Improv-
ing our understanding of the physiological processes
underlying dysbiosis:disease relationships is crucial not
only for developing new interventions, but also for estab-
lishing biological and associated regulatory standards
and guidance to facilitate timely approval and implemen-
tation of novel biomedical interventions.
Synthetic microbiota for therapies
The trend will thus inexorably be towards the develop-
ment of single, extremely well-characterized, pure and
fermenter-propagated microbial strains, for those condi-
tions for which single strains prove to be effective thera-
peutics. This is not only because of simplicity, safety,
standardization, quality control and regulatory issues, but
also because of the imperative of further development for
improved effectiveness, predictability, etc., and the perti-
nent potential that powerful synthetic microbiology design
approaches offer. And, most importantly, because single
strain therapies will greatly simplify the experimental
investigation of underlying ecophysiological processes
and establishment of causalities.
However, since dysbiosis involves complex composi-
tional, and especially functional, ecophysiological
changes in the microbiota, restoration of a healthy micro-
biota will often require the administration of multiple,
functionally diverse strains delivered in the form of a
coherent community. While one approach may be to
simplify a natural community, such as one derived from
a faecal sample – for example by propagation in an arti-
ficial gut bioreactor – its relatively poorly characterized
members may still pose risks and issues of reliability
and reproducibility. Alternatively, synthetic consortia
assembled from well characterized individual strains,
propagated as pure cultures, may be developed that
exhibit low risk profiles, and properties that are standard-
ized, predictable and effective.
Design of physically-linked microbial consortia by
means of nanobody surface display
The main challenge facing the use of synthetic consortia
is their lack of intrinsic physical and functional cohesion,
and their uncertain ecological fate in situ. In particular
the potential for rapid loss of one or more members, due
for example to poor competitivity in dynamic environ-
ments like the GI tract, and the possible ensuing loss of
beneficial functionalities of the administered consortium,
can impede intervention effectiveness.
To counteract a possible lack of coherence of a syn-
thetic consortium when propagated in a natural setting, de
Lorenzo proposed in 2008 the use of surface displayed
recombinant antibodies – nanobodies (Nbs) – to physi-
cally link the consortium partners (de Lorenzo, 2008; see
also Veiga et al., 2003). Nbs are recombinant single
domain antibodies derived from the variable regions of a
special class of immunoglobulins lacking light chains that
are naturally present in members of the camelidae (e.g.
camels, dromedaries, llamas, alpacas, etc.; (Muylder-
mans, 2013). The variable regions of heavy chain-only
antibodies (HCAbs), referred to as VHH in Fig. 1A, have
multiple adaptations that endow them with solubility and
the ability to bind antigens (Ags) in the absence of a
paired light chain. The small size (ca. 14 kDa) and supe-
rior biophysical and antigen-binding properties of Nbs
make them ideal candidates for diverse applications
requiring the selective recognition and binding to Ags of
different entities, including viruses, bacteria, and eukary-
otic cell targets (Oliveira et al., 2013; Chakravarty et al.,
2014; Steeland et al., 2016; Van Audenhove and Gette-
mans, 2016). Importantly, high affinity Nbs of desired
specificity can be selected from libraries of VHH gene seg-
ments, amplified from peripheral blood lymphocytes of
immunized animals, and cloned and expressed in bacte-
riophages, E. coli or yeast cells (Salema and Fernandez,
2017).
For the purpose of displaying Nbs on the bacterial
surface, they are fused to an N-fragment of intimin
(residues 1–654), comprising its ß-barrel and first extra-
cellular Ig-like domain (D0) (Fig. 1B), which stably
anchors them in the outer membrane of Gram negative
bacteria. The intimin anchor is highly stable vis-a-vis
strong denaturants (e.g. SDS, urea) and proteases (e.g.
trypsin) (Bodelon et al., 2009), allows for high density
display of Nbs on E. coli surfaces, and thereby the effi-
cient selection of binders from VHH libraries (Salema
et al., 2013). Importantly, intimin-Nb fusions have been
shown to constitute robust synthetic adhesins for
E. coli, that mediate their rapid and specific bonding to
cognate antigens on target cells (Pi~nero-Lambea et al.,
2015a).
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Recent progress has shown that Nbs can be used for
the controlled formation of combinations of different
E. coli derivatives (Glass and Riedel-Kruse, 2018) in pre-
defined architectures, and provided proof of principle of
the design of synthetic consortia based on what might
be called a ‘bait’ strain displaying Nbs, that stably bind
to one or multiple target strains bearing cognate Ags,
either natural or engineered, expressed on their surfaces
(Fig. 2A–C). For microbiota therapies, either the bait
strain or one of the target strains should be a good colo-
nizer of the target organ in order that the synthetic con-
sortium persists in situ for the period needed for
attainment of the therapeutic effect.
By enabling the a la carte modular design and genera-
tion of synthetic, physically-linked consortia of well-char-
acterized microbes, the nanobody surface display
platform assures the functional coherence needed for
synthetic microbiology-based precision medicine inter-
ventions, and thus opens up the field for novel
approaches to treating microbiota dysbiosis. The chal-
lenge is to identify, characterize and demonstrate effi-
cacy and, subsequently, effectiveness, of strains
appropriate for this purpose (for a light-hearted treatment
of some of the relevant issues, see Timmis et al., 2019,
this issue).
Further potential applications of nanobody surface
display in live microbe therapies
The nanobody surface display platform also enables the
specific targeting of individual microbes, and designed
consortia, to other relevant biological surfaces of interest,
for example, those of epithelial cells, to prolong resi-
dence time and hence therapy duration, or of the gut-
associated lymphoid tissue (e.g. Peyer’s Patches), to
achieve immunomodulatory goals, such as stimulation of
mucosal immunity against specifically-presented anti-
gens, or localized secretion of anti-inflammatory cytoki-
nes or antibodies produced by one or more of the
delivered bacteria (Pi~nero-Lambea et al., 2015b;
Bermudez-Humaran and Langella, 2018).
Creating individual microbes, or combinations thereof,
that target and bind to GI tract mucosal epithelial cells and
produce beneficial metabolites may enhance absorption
of such metabolites by the gut (Fig. 3) (Chen et al., 2014).
Alternatively, consortia may be designed both to eliminate
toxic metabolites, such as phenylalanine in patients with
phenylketonuria (Isabella et al., 2018), and to attach to
the host mucosal surface, to create a bioactive barrier that
reduces the uptake of such metabolites (Fig. 3). Another
potential application of particular interest in relation to the
current antibiotic resistance threat is to combine expres-
sion of Nbs specific for surface localized Ags of patho-
genic bacteria, and antibacterial products, such as
microcins (Hwang et al., 2017) or toxins delivered by type
6 secretion systems (Alcoforado Diniz et al., 2015; Chas-
saing and Cascales, 2018), in order to target and kill
pathogens, and hence reduce disease severity and dura-
tion. A particularly interesting potential application of Nb
engineered bacteria is in tumour imaging and therapy
using bacteria exhibiting tropisms for tumours (Felgner
et al., 2017): Pi~nero-Lambea et al. (2015a) report that
Fig. 1. Nanobody display and synthetic adhesins of Escherichia coli. A. Structure of a camelid heavy chain-only antibody (HCAb), indicating
the constant Fc region and variable VHH domains. Nanobodies (Nbs) are the antigen-binding VHH domains produced by engineered microbes.
B. Surface display of Nbs on the E. coli cell surface, through their fusion to intimin N-fragment 1-654 comprising ß-barrel and Ig-like D0 domain,
which anchors the Nb to the bacterial outer membrane (OM).
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non-pathogenic E. coli bacteria displaying synthetic adhe-
sins against tumour cells effectively colonize solid
tumours at doses two-orders of magnitude lower than
those needed with control bacteria, suggesting a means
of reducing the risks of this type of bacterial therapy
(Chien et al., 2017). Such potential live therapeutic inter-
ventions (see e.g. Alvarez and Fernandez, 2017), and
others, now acquire a new developmental potential,
through the possibility of Nb-mediated addition of one or
more microbial partners able to contribute further benefi-
cial functionalities.
Multimorbidity and potential applications of synthetic
microbiota in precision prophylaxes and therapies
One major, and arguably the most alarming, trend in the
healthcare domain is multimorbidity. For example,
according to a recent (2018) review for the UK (Tran
et al., 2018), the number of individuals with incident car-
diovascular disease and at least 5 co-morbidities
increased fourfold between 2000 and 2014, with 60% of
co-morbidities being of cardiometabolic nature (the most
serious of which are chronic kidney disease, diabetes
mellitus, hyperlipidaemia, hypertension, obesity and
peripheral arterial disease). Based on current trends for
diabetes mellitus, hypertension and obesity incidence,
and tobacco consumption, cardiovascular mortality rates
for individuals below 70 years of age are projected to
increase by more than 30% globally over the next dec-
ade, to ca. 8 million deaths per annum (Antman and
Loscalzo, 2016). Importantly, disease:disease interac-
tions and polypharmacy (that often leads to serious
adverse drug reactions caused by conflicting medica-
tions (see e.g. Bouvy et al., 2015)), frequently exacer-
bate health deterioration – the mechanisms of which
mostly remain poorly understood at the molecular
Fig. 2. Designed nanobody-linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens
on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbio-
sis co-morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi-functional
microbiota therapy (D).
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level – and limit treatment options for multimorbid
patients (see e.g. Ording and Sorensen, 2013; Battegay
et al., 2017;).2
The example of cardiovascular and cardiometabolic dis-
ease(s) is particularly relevant to the issue of microbiome
therapies because both have been associated with micro-
biome dysbiosis, and hence may in some instances repre-
sent dysbiosis-associated morbidity clusters. Moreover,
as further microbiome dysbiosis-associated diseases are
discovered, and our understanding of the ecophysiologi-
cal-metabolic-regulatory processes underlying dysbiosis
and disease advances, it is to be expected that multiple
distinct root causes of specific microbiota dysbiosis phe-
notypes and associated specific disease symptoms will
be identified, that, in turn, will increasingly require disease
reclassification based on cause. For example, a condition
like obesity may well be a clinical phenotype that will sub-
sequently be revealed to encompass several distinct dis-
eases (leading e.g. to the identification of type 1, 2, 3,
etc., obesity). The existence of dysbiosis-associated mor-
bidity clusters, some of which will necessitate two or more,
perhaps confounding, therapeutic consortia having dis-
tinct therapeutic aims is therefore not unlikely.3 However,
although multimorbidity will significantly increase compli-
cations of therapeutic material preparation, treatment and
Fig. 3. Further potential therapeutic applications of synthetic consortia linked by surface-displayed nanobodies. The figure portrays various
interactions of synthetic consortia and the host microbiota and/or niches and tissue sites of the gastrointestinal tract mediating therapeutic
activities. For instance, engineered bacterial strains in the consortia may deliver antigens or release biotherapeutics (e.g. antibodies, cytokines)
locally to promote immune responses, e.g. in the Peyer’s Patches, or reduce mucosal inflammation. Bacteria in the synthetic consortia may also
display nanobodies to “trap” pathogens and kill them specifically by delivery of antibacterial toxins (e.g. microcins, effectors of type 6 secretion
systems). These activities may favour colonization of the gastrointestinal tract by beneficial commensals during and after disease and dysbiosis.
In addition, nanobody-driven attachment of synthetic consortia to the mucosal surface may enhance therapeutic actions either favouring or
preventing the absorption of specific metabolites by the host.
2A major problem associated with multimorbidity is the fact that,
although over the past two decades multimorbidity incidence, or
rather the recognition thereof, and overall expenditures for multimor-
bidity management have increased at an accelerating rate, evidence
of efficacy, effectiveness and efficiency of conventional (one-size-
fits-all) treatments, let alone of precision (personalized) medicine
interventions, for multimorbidity is scarce and clinical guidelines are
virtually non-existent. One important reason is that conventional ran-
domised clinical trials, which are considered the gold standard trial
design, usually test one diagnostic and/or intervention targeting one
specific condition/genotype and tend to explicitly exclude multi-mor-
bid patients in order to reduce the risk of bias and confounders, and
to control for externalities (Ording and Sorensen, 2013; Battegay
et al., 2017; Tran et al., 2018).
3A further complication would be co-morbidities involving both a
classical disease, like cancer, and a microbiota dysbiosis-associated
disease, where the traditional therapy may affect the microbiota
therapy.
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monitoring, the nanobody surface display platform, which
is in principle upscalable in terms of the number of mem-
bers of the synthetic consortium, should allow the con-
struction of bi/multifunctional, non-confounding consortia
(Fig. 2D) that have the same preparation, treatment and
monitoring requirements as monofunctional consortia.
As stated above, it is to be expected that there will be
considerable variation in the causes of microbiota dys-
biosis, as well as individual-specific variation in disease
manifestation, responses and therapy effectiveness pro-
files, even for patients with similar symptoms. This host-
specific variation is the basis of precision/personalized
medicine – in its current form, the design of treatments
for specific patient cohorts but, in future, increasingly the
tailoring of interventions to individual patients (Jameson
and Longo, 2015). Future precision medicine will
undoubtedly include the personalization of live microbial
communities for the treatment of microbiota dysbioses. A
growing toolbox of well-characterized and -tested strains
exhibiting known therapeutic functionalities, together with
the Nb surface display platform for the creation of a la
carte consortium combinations, will not only provide the
means of creation of individual therapies but also enable
advancement of our understanding of the basis of such
host variations.
The wider context: systems medicine and translation
As alluded to above, our current understanding of causal
relationships between microbiome dysbiosis and the
aetiology of a variety of diseases, and clusters thereof,
is in its infancy. However, recent advances in genome
mapping and genome-wide association studies and next
generation sequencing, increases in the capacity and
sophistication of big-data collection and analytics (e.g.
machine learning), utilization of electronic health records,
etc., and the orientation towards a biomolecular network-
based, multidisciplinary and holistic systems medicine
approach – the application of the principles of systems
biology to the modern healthcare field (Hood et al.,
2004, 2012) – have revolutionized biomedical research
and development. Systems medicine is significantly
advancing our understanding of, and thereby redefining,
what constitutes health and disease (in relative terms),
and which perturbations in protein and gene regulatory
networks cause or predict a shift in the health:disease
continuum (Sagner et al., 2017). This approach has
already facilitated significant advances in health tech-
nologies, such as biomarker based liquid biopsy molecu-
lar diagnostics (Noell et al., 2018), and will in the future
even more rapidly transform methods and techniques to
investigate and analyse complex data-sets, develop new
diagnostics, prophylaxes and therapeutics to address
complex and pressing healthcare needs with modern
and stratified clinical interventions (Wolkenhauer et al.,
2013; Bjornson et al., 2016; Apweiler et al., 2018; Noell
et al., 2018). Although pervasively important for develop-
ing novel pharmacogenomic precision medicine interven-
tions, such as recently introduced antibody-based
immunotherapies for leukaemia (see e.g. Maude et al.,
2018), the systems medicine approach lends itself per-
fectly to the exploration and development of novel syn-
thetic, scalable and modular microbial consortia-based
precision medicine interventions that are being dis-
cussed here.
Central to maximising both the leverage of the sys-
tems medicine approach for research and development
of microbiome dysbiosis-based novel interventions, and
their effective and timely translation into clinical practice
– will be inter alia
(i) the institution of population-wide periodic microbiome
sampling and analyses, i.e. data collection and inter-
rogation (see e.g. Timmis and Timmis, 2017),
(ii) a shift towards more appropriate financing mecha-
nisms (e.g. combined push- and pull-incentives) to
streamline translation and trialling of promising novel
interventions (Renwick and Mossialos, 2018), and
(iii) utilization of knowledge valorization models to reduce
information asymmetries between stakeholders and,
in turn, improve the prospects of commercialising rel-
evant new knowledge generated in public and private
research and development organizations (Van de
Burgwal et al., 2018).
Conclusions
In summary, gazing into our Crystal Ball, we see the
nanobody surface display approach at the centre of
prevention and therapy measures for microbiota dysbio-
sis-associated diseases, and indeed for other live
microbe-based interventions, in providing the glue of a
technology platform (see e.g. Fraile et al., 2013) for the
a la carte assembly of precise, modular, stable, synthetic
consortia with designed functionalities for systems medi-
cine-based precision interventions. A growing toolbox of
well-characterized consortium members of proven utility
will form the modules for consortium assembly. Such
highly characterized modules and simple consortia will
facilitate the development of improved, second genera-
tion microbial therapies, especially through the applica-
tion of synthetic microbiology approaches. Most
importantly, they will enable experimental investigation of
underlying ecophysiological and metabolic processes
and causalities of complex host:microbiota:symptom
interactions that are currently black boxes, and thereby
ultimately lead to a fundamental understanding of both
physiology and dysbiosis of our microbiome surfaces,
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especially of the GI tract, and diseases channelled via
the various gut-organ axes.
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